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EDITORIAL
Alport syndrome: Is diagnosis only skin-deep?
The discovery that Alport syndrome results from type cal analysis of a skin biopsy specimen for EBM expres-
IV collagen mutations [1, 2] had its genesis in the seminal sion of the a5(IV) chain. What is the appropriate role
observation that IgG in sera from patients with anti- for skin biopsy in the evaluation of a patient with micro-
glomerular basement membrane (GBM) nephritis fails hematuria who is suspected to have XLAS? As Figure
to bind to the GBM of Alport males [3]. This notable 1 indicates, one possible approach to diagnosis would
finding was followed by reports of Alport patients who be to perform a skin biopsy with immunohistochemical
developed anti-GBM nephritis in their renal allografts analysis of a5(IV) expression. Absence of a5(IV) expres-
[4, 5]. Anti-GBM IgG from these patients stained GBM sion in a male, or clearly mosaic a5(IV) expression in a
in normal kidneys, but not the GBM of the patients’ native female, is diagnostic of XLAS arising from a COL4A5
kidneys, suggesting that Alport GBM was lacking a nor- mutation. Normal expression of a5(IV) in the skin of a
mal constituent. Pioneering studies establishing type IV patient suspected of Alport syndrome has several possi-
collagen as the target of Goodpasture autoantibodies [6] ble explanations: (1) the patient has a COL4A5 mutation
led to the recognition that the anti-GBM alloantibodies that allows skin expression of a5(IV), as in one of van der
of transplanted Alport patients were also directed against Loop et al’s patients [14]; (2) the patient has autosomal
type IV collagen [5], setting the stage for the integration recessive Alport syndrome, as first described by Gubler
of gene mapping [7] and biochemical [8] data that pre- and colleagues and confirmed here by van der Loop et
ceded the cloning of the X-chromosomal COL4A5 gene al [14, 18]; (3) the patient has a disease other than Alport
and the description of its product, the a5 chain of type syndrome. If skin expression of a5(IV) is normal, the
IV collagen [a5(IV)] [9]. Over 200 mutations in type next step would be kidney biopsy. Analysis of type IV
IV collagen genes causing Alport syndrome have been collagen expression in the kidney, combined with routine
identified [reviewed in 10], and type IV collagen muta- light, immunofluorescence and electron microscopy, will
tions have been implicated in the pathogenesis of benign in most cases allow differentiation of Alport syndrome
familial hematuria [11] and leiomyomatosis [12, 13]. from other renal diseases.
We noted that anti-GBM IgG from a transplanted Al- What is the role of molecular genetic analysis in the
port patient bound to normal epidermal basement mem- evaluation of patients and families with Alport syn-
branes (EBM), but not to the patient’s own EBM or the drome? As van der Loop and colleagues indicate, the
EBM of other Alport males [5]. Affected females in sequencing of type IV collagen genes is very laborious,
families with X-linked Alport syndrome (XLAS) exhib- and at present is not readily available to many clinicians.
ited mosaic reactivity with this anti-GBM IgG, consistent Once a diagnosis of XLAS is confirmed by skin or kidney
with the consequences of random X inactivation. Re- biopsy, the fact that the patient has a progressive ne-
cently, this Alport anti-GBM IgG was shown to be di- phropathy is established, the great majority of affected
rected against the a5(IV) chain [14]. MoabA7, the mono- relatives can be identified by urinalysis, and genetic coun-
clonal antibody used in the study in this issue of Kidney seling can be provided. Thus, important questions can
International by van der Loop and colleagues [15], was be answered without knowing the causative mutation in
generated by immunization of a Balb/c mouse with the a particular family. However, molecular genetic analysis,
collagenase resistant residue of normal human GBM either through linkage analysis or mutation identifica-
[16]. MoabA7 was found to react with tissues, including
tion, is the only means by which to absolutely exclude
EBM, and isolated GBM in a fashion identical to the
the carrier state in an asymptomatic female member ofAlport anti-GBM IgG [16], and to specifically identify
a kindred with XLAS, and the only way to detect Alportthe a5(IV) chain [17].
syndrome prenatally. Molecular genetic analysis wouldThe study by van der Loop et al and previous studies
also be appropriate when the diagnosis of Alport syn-referenced in their article clearly indicate that in a sub-
drome cannot be excluded unequivocally by biopsy, orstantial percentage of candidate families an unequivocal
when the inheritance of Alport syndrome in a familydiagnosis of XLAS can be made by immunohistochemi-
cannot be determined by pedigree analysis and/or immu-
nohistochemical evaluation. Eventually, automation and
Key words: inherited disease, type IV collagen, familial hematuria. miniaturization of genetic diagnostic techniques may
allow widespread application of molecular genetic analy- 1999 by the International Society of Nephrology
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